Drug Trial Radar · NCT06799065
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Mar 21, 2025
Primary completion
Apr 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Accent TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 as a monotherapy and in combination with bevacizumab (or a biosimilar) in patients with locally advanced or metastatic solid tumors, including ovarian cancer and lung cancer.
Conditions
- Advanced Solid Tumors
- Breast Cancer Recurrent
- Ovarian Cancer
- High-grade Serous Ovarian Carcinoma
- Triple Negative Breast Cancer
- sqNSCLC
- Squamous Non-small-cell Lung Cancer
Interventions
ATX-295Drug
ATX-295 tablets will be taken orally
ATX-295 and bevacizumab (or biosimilar)Drug
ATX-295 tablets will be taken orally in combination with bevacizumab (or biosimilar) administered via intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of ATX-295 as a monotherapy and in combination with bevacizumab (or biosimilar)Time frame: 12 months
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: 12 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Denver
Aurora, Colorado · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
NYU Longone Health (Long Island)
Long Island City, New York · Recruiting
NYU Longone Health (Manhattan)
Manhattan, New York · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.